OncoTartis, Inc. has engaged Dr. Eric Rowinsky to serve an acting Medical Director for the upcoming clinical trial of its drug candidate OT-82, a small molecule with anti-leukemia and anti-lymphoma activities. Dr. Rowinsky has more than 25 years of experience managing clinical trials and developing drugs in oncology, including leading the Food and Drug Administration, or FDA, approval of Erbitux® for head and neck and colorectal cancers and advancing eight other biological therapeutics through clinical development while at ImClone. He completed a medical oncology fellowship at The Johns Hopkins Hospital. Dr. Rowinsky was an Associate Professor of Oncology at Johns Hopkins and then Head of Clinical Research and Director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio, Texas.